Targeted Agents for Chronic Myelogenous Leukemia: Will That Be the End of Allogeneic Bone Marrow Transplantation for That Disease?

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 6, 2010, Pages 848-853

  Liang, Yuzhen ^a   Lai, Yongrong ^a   Schwarzenberger, Paul ^b   Li, Qiaochuan ^a   Ma, Jie ^a   Luo, Jun ^a   Liu, Rongrong ^a   Shi, Lingling ^a   Zhou, Jicheng ^a   Peng, Zhigang ^a   Yang, Jie ^a   Deng, Donghong ^a   Zhou, Yizhen ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b University of South Alabama   (China)

Author keywords

Allogeneic peripheral blood SCT; CML; GVHD; Prophylaxis

Indexed keywords

CYCLOSPORIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADOLESCENT; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DRUG DOSE REDUCTION; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; MALE; OVERALL SURVIVAL; SCHOOL CHILD; SURVIVAL TIME;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CHILD; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG THERAPY; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PIPERAZINES; PYRIMIDINES; RECURRENCE; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952570012     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.01.016     Document Type: Article

References (46)

1. Nowell P.C., Hungerford D.A. A minute chromosome in human chronic granulo-cytic leukemia. Science 1960, 132:1497.
2. Rowley J.D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290-293.
3. Hehlmann R., Hochhaus A., Baccarani M. European Leukemia Net. Chronic myeloid leukaemia. Lancet 2007, 370:342-350.
4. Sawyers C. Chronic myeloid leukaemia. N Engl J Med 1999, 340:1330-1340.
5. Druker B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112:4808-4817.
6. Passweg J.R., Walker I., Sobocinski K.A., et al. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 2004, 125:613-620.
7. Baccarani M., Saglio G., Goldman J., et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006, 108:1809-1820.
8. Gratwohl A., Brand R., Apperley J., et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006, 91:513-521.
9. Copelan E.A. Hematopoietic stem-cell transplantation. N Engl J Med 2006, 354:1813-1826.
10. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
11. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037.
12. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
13. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
14. O'Brien S.G., Guilhot F., Gathmann I., et al. International randomized study of interferon versus ST1571(IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 2008, 112:86.
15. Hehlmann R., Berger U., Pfirrmann M., et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloidleukemia. Blood 2007, 109:4686-4692.
16. Bittencourt H., Funke V., Fogliatto L., et al. Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase. Bone Marrow Transplant 2008, 42:597-600.
17. Ruiz-Arguelles G.J., Tarin-Arzaga L.C., Gonzalez-Carrillo M.L., et al. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era:SCT or TKIs?. Bone Marrow Transplant 2008, 42:23-28.
18. GajewskiJL Robinson P Do affluent societies have the only options for the best therapy?. Leukemia 2007, 21:387-388.
19. Lai Y., Ma J., Schwarzenberger P., et al. Combination of CsA, MTX and low-dose, short-course mycophenolate mofetil for GVHD prophylaxis. Bone Marrow Transplant 2009, 43:61-67.
20. Gratwohl A., Hermans J., Goldman J.M., et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998, 352:1087-1092.
21. Mughal T.I., Yong A., Szydlo R., et al. The probability of long-term leukaemia free survival for patients in molecular remission 5years after allogeneic stem cell transplantation for chronic myeloid leukaemia in chronic phase. Br J Haematol 2001, 115:569-574.
22. Gratwohl A., Brand R., Frassoni F., et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 2005, 36:757-769.
23. Radich J.P., Gooley T., Bensinger W., et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003, 102:31-35.
24. Or R., Shapira M.Y., Resnick I., et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003, 101:441-445.
25. Bensinger W.I., Martin P.J., Storer B., et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001, 344:175-181.
26. Couban S., Simpson D.R., Barnett M.J., et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002, 100:1525-1531.
27. Schmitz N., Beksac M., Hasenclever D., et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002, 100:761-767.
28. Tanimoto T.E., Yamaguchi T., Tanaka Y., et al. Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients. Br J Haematol 2004, 125:480-493.
29. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005, 23:5074-5087. Stem Cell Trialists' Collaborative Group.
30. Liu Q.F., Sun J., Zhang Y., et al. Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia. Chin J Cancer 2004, 23:426-429. (Chinese).
31. He Y., Feng S.Z., Wang M., et al. HLA-identical sibling allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia in first chronic phase. Analysis of 51 cases. Chin J Hematol 2005, 26:389-392. (Chinese).
32. Liu D., Guo N., Zhang Y. Allogeneic bone marrow transplantation for chronic myeloid leukemia: 118 cases analysis. Chin J Hematol 1999, 20:424-426. (Chinese).
33. Kantarjian H.M., O'Brien S., Cortes J.E., et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002, 100:1590-1595.
34. DeAngelo D.J., Hochberg E.P., Alyea E.P., et al. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res 2004, 10:5065-5071.
35. Jabbour E., Cortes J., Kantarjian H.M., et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 2006, 108:1421-1423.
36. Weisser M., Schleuning M., Haferlach C., et al. Allogeneic stem-cell transplantation provides excellent results in dvanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leuk Lymphoma 2007, 48:295-301.
37. Carpenter P.A., Snyder D.S., Flowers M.E.D., et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007, 109:2791-2793.
38. Poiré X., Artz A., Larson R.A., et al. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma 2009, 50:85-91.
39. Steegmann J.L., Casado L.F., Tomás J.F., et al. Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999, 23:483-488.
40. Posthuma E.F., Marijt E.W., Barge R.M., et al. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Biol Blood Marrow Transplant 2004, 10:204-212.
41. Kaeda J., O'Shea D., Szydlo R.M., et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood 2006, 107:4171-4176.
42. Guglielmi C., Arcese W., Hermans J., et al. Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. The Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2000, 95:3328-3334.
43. Olavarria E., Ottmann O.G., Deininger M., et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myloid leukemia. Leukemia 2003, 17:1707-1712.
44. Weisser M., Tischer J., Schnittger S., et al. A comparison of donor lymphocyte infusion or imatinib mesylate for patients with chronic mylogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 2006, 91:663-666.
45. Deininger M., Schleuning M., Greinix H., et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 2006, 91:452-459.
46. Lee S.J., Kukreja M., Wang T., et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 2008, 112:3500-3507.